Skip to main content
    G

    Goodrx Holdings Inc (GDRX)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $3.50
    +0.12 (+3.70%)

    Market Cap: $1.15B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(17/25)
    Avg Surprise
    +1712.89%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.08
    Range$0.07 - $0.10
    11 analysts
    EPS Revisions
    1
    0
    7d
    3
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$0.08-2.3%
    60d ago$0.08-3.9%
    30d ago$0.08-0.8%
    7d ago$0.080.0%
    Current$0.08
    Revenue Consensus
    $202M
    Range$199M - $205M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.07
    Range$0.06 - $0.11
    11 analysts
    Revenue Consensus
    $218M
    Range$210M - $222M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.07---
    Sep 26EST
    		-$0.08---
    Jun 26
    Reported Aug 5
    		$0.04$0.04+0.00%Beat-55.6%
    Mar 26
    Reported May 6
    		$0.07$0.07+0.00%Beat-22.2%
    Dec 25
    Reported Feb 25
    		$0.09$0.09-1.85%Miss+0.0%
    Sep 25
    Reported Nov 4
    		$0.08$0.09-11.11%Miss+0.0%
    Jun 25
    Reported Aug 6
    		$0.09$0.10-10.00%Miss+12.5%
    Mar 25
    Reported May 7
    		$0.09$0.10-5.96%Miss+12.5%
    Dec 24
    Reported Feb 27
    		$0.09$0.10-10.00%Miss+12.5%
    Sep 24
    Reported Nov 7
    		$0.08$0.09-11.11%Miss+33.3%
    Jun 24
    Reported Aug 8
    		$0.08$0.09-11.11%Miss+14.3%
    Mar 24
    Reported May 9
    		$0.08$0.08+0.00%Beat+14.3%
    Dec 23
    Reported Feb 29
    		$0.08$0.07+14.29%Beat+14.3%
    Sep 23
    Reported Nov 9
    		$0.06$0.06+0.00%Beat-14.3%
    Jun 23
    Reported Aug 9
    		$0.07$0.06+16.67%Beat+16.7%
    Mar 23
    Reported May 10
    		$0.07$0.06+16.67%Beat-30.0%
    Dec 22
    Reported Feb 28
    		$0.07$0.05+40.00%Beat-22.2%
    Sep 22
    Reported Nov 8
    		$0.07$0.04+75.00%Beat-22.2%
    Jun 22
    Reported Aug 8
    		$0.06$0.04+50.00%Beat-25.0%
    Mar 22
    Reported May 9
    		$0.10$0.08+25.00%Beat+42.9%
    Dec 21
    Reported Feb 28
    		$0.09$0.10-10.00%Miss+12.5%
    Sep 21
    Reported Nov 10
    		$0.09$0.09+0.00%Beat+0.0%
    Jun 21
    Reported Aug 12
    		$0.08$0.08+0.00%Beat-99.8%
    Mar 21
    Reported May 13
    		$0.07$0.07+0.00%Beat-
    Dec 20
    Reported Mar 11
    		$0.08$0.06+33.33%Beat-
    Sep 20
    Reported Nov 12
    		$0.09$0.08+12.50%Beat-
    Jun 20
    Reported Jul 2
    		$42.71$0.10+42610.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio12.52EV/EBITDA8.31x
    Price/FCF9.03xFCF Yield11.07%
    Profitability
    Profit Margin2.07%Operating Margin11.80%
    ROE2.52%ROIC4.33%
    Financial Health
    Debt/Equity0.75xInterest Coverage1.85x
    Current Ratio1.38xQuick Ratio1.38x
    Trading Statistics
    Beta1.69Avg Volume832.22K
    52-Week High$4.0552-Week Low$1.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.38
    SMA 20$3.36
    SMA 50$3.47
    SMA 200$2.78
    EMA 10$3.40
    EMA 20$3.39
    EMA 50$3.35
    EMA 200$3.13

    MACD

    Line: 0.01Signal: -0.01Hist: 0.02

    ADX

    ADX: 17.4+DI: 29.4-DI: 15.1

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down64.0
    PSAR$3.26

    Bollinger Bands

    Upper Band$3.51
    Lower Band$3.20
    %B Position935%(Upper)
    Band Width0.98

    RSI (14-Day)

    Neutral
    57.2

    Momentum Oscillators

    Stoch %K70.0
    Stoch %D74.8
    Williams %R-12.9
    ROC (10d)7.2%
    Momentum0.23
    CCI (20d)139.1
    MFI (14d)58.5

    Volatility Measures

    ATR (14d)$0.12(3.4%)
    StdDev (20d)0.08
    Hist Vol31.9%(Moderate)

    Volume Flow

    VWAP$3.48
    OBV53.9M
    AD Line-68.8M
    CMF (20d)0.024

    Volume Metrics

    Avg Vol (20d)840.3K
    Vol Ratio2.3x(High)
    VWMA (20d)$3.37

    Pivot Points

    R3$3.53
    R2$3.49
    R1$3.44
    Pivot Point$3.40
    S1$3.35
    S2$3.31
    S3$3.26

    Advanced Oscillators

    TSI1.67
    Ultimate Osc53.0
    KST-29.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$200.41M$194.01M$194.78M$196.03M$203.07M$202.97M$198.58M$195.25M$200.61M$197.88M$196.64M$179.96M
    Cost of Revenue$21.00M$20.16M$17.46M$13.42M$13.35M$13.36M$12.19M$11.68M$11.87M$12.47M$15.17M$18.72M
    Gross Profit$179.41M$173.85M$177.32M$182.61M$189.72M$189.61M$186.39M$183.57M$188.74M$185.41M$181.47M$161.24M
    Operating Expenses$155.78M$159.84M$154.64M$167.99M$162.91M$166.23M$168.21M$163.16M$168.86M$178.03M$199.76M$199.57M
    R&D$26.71M$30.18M$28.94M$31.01M$29.93M$31.14M$31.74M$30.14M$30.85M$31.02M$32.03M$39.61M
    SG&A$24.81M$26.82M$23.94M$32.01M$28.38M$29.63M$23.55M$25.62M$27.59M$41.11M$30.37M$35.32M
    Operating Income$23.63M$14.01M$22.68M$14.62M$26.81M$23.38M$18.18M$20.41M$19.88M$7.38M$-18,288,000$-38,330,000
    Interest Income$1.02M$1.40M$1.89M$2.31M$2.80M$3.93M$4.59M$4.80M$6.33M$7.55M$8.47M$8.65M
    Interest Expense$9.81M$9.77M$10.40M$10.83M$10.73M$10.64M$11.36M$14.43M$14.57M$14.64M$14.82M$14.72M
    Income Before Tax$15.47M$5.64M$14.19M$6.10M$19.58M$16.67M$11.41M$8.11M$11.65M$293,000$-24,635,000$-46,601,000
    Income Tax Expense$6.93M$4.47M$8.77M$4.98M$6.73M$5.62M$4.67M$4.15M$4.95M$1.30M$1.23M$-8,106,000
    Net Income$8.54M$1.17M$5.42M$1.12M$12.84M$11.05M$6.74M$3.96M$6.69M$-1,009,000$-25,869,000$-38,495,000
    EBITDA$47.00M$36.26M$46.28M$36.50M$47.67M$44.72M$37.70M$35.70M$37.67M$24.16M$26.16M$-6,662,000
    EBIT$24.26M$14.01M$22.68M$14.62M$27.50M$23.38M$18.18M$17.75M$19.88M$7.38M$-18,288,000$-40,530,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GDRX

    News

    Here's what you need to know about the no-proof GoodRX $32 million user privacy class action settlement!

    GoodRx has agreed to a $32 million class action settlement for allegedly sharing users' personal and health information with third-party advertisers without consent. Individuals who used any GoodRx service before April...

    Claim Depot•10/14/26•Bearish

    Enterprise value to EBITDA forward of GoodRx Holdings, Inc. Class A – FWB:8GH

    This article provides the enterprise value to EBITDA forward for GoodRx Holdings, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:8GH. It details financial data available through TradingView...

    TradingView•9/20/26•Neutral

    GoodRx CAO Thomas Chan Reports RSU Vesting and Tax-Related Share Withholding on September 15, 2026

    GoodRx Chief Accounting Officer Thomas Chan reported the vesting of 2,101 restricted stock units (RSUs) into Class A Common Stock on September 15, 2026. Simultaneously...

    Kalkine Media•9/15/26•Neutral

    GoodRx CFO Justin Fengler Reports RSU Vesting and Share Withholding on September 15, 2026

    GoodRx CFO Justin Fengler reported the vesting of restricted stock units (RSUs) and the corresponding share withholding for tax liabilities on September 15, 2026. This involved two separate RSU awards...

    Kalkine Media•9/15/26•Neutral

    GoodRx (NASDAQ:GDRX) 10% owner Francisco Partners sells $5.48m in stock

    Francisco Partners, a 10% owner of GoodRx Holdings, Inc. (NASDAQ:GDRX), recently sold approximately $5.48 million worth of Class A Common Stock through several transactions in late August 2026. Despite these insider...

    Investing.com Nigeria•8/26/26•Somewhat-Bearish

    GDRX Valuation and Fair Value

    P/E
    12.5x
    Forward P/E
    10.3x
    EV/EBITDA
    8.3x
    P/FCF
    9.0x
    P/B
    1.8x
    See GNG's fair value

    GDRX Profitability: Margins, ROIC and FCF

    Gross margin
    90.8%
    Operating margin
    11.8%
    Net margin
    2.1%
    ROIC
    4.3%
    ROE
    2.5%
    FCF margin
    16.8%
    FCF yield
    11.1%

    GDRX Competitors

    CompanyTicker
    Cronos Group IncCRON
    Iradimed CoIRMD
    CareCloud, Inc.CCLDO
    Taysha Gene Therapies IncTSHA
    Oric Pharmaceuticals IncORIC
    Vor Biopharma IncVOR
    Tourmaline Bio Inc.TRML
    Omada Health, Inc. Common StockOMDA

    Sector: Healthcare

    GDRX Analyst Ratings

    Consensus
    Hold
    Analysts
    14
    Strong Buy
    1
    Buy
    3
    Hold
    8
    Sell
    0
    Strong Sell
    2

    GDRX Bull Case vs Bear Case

    Bull case

    • GDRX converts 16.8% of revenue into free cash flow.

    Bear case

    • GDRX beat EPS estimates in 0.0% of its last 8 reported quarters.
    • GDRX's quarterly revenue changed -1.3% year over year.

    GDRX Earnings: Beat Rate and Next Report

    Beat rate
    0 of 8 quarters (0.0%)
    Average surprise
    -6.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.08
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 4 down

    Frequently Asked Questions About GDRX

    Does GDRX pay dividends?

    Goodrx Holdings Inc (GDRX) does not currently pay a regular dividend.

    What is GDRX's P/E ratio?

    Goodrx Holdings Inc has a price-to-earnings (P/E) ratio of 12.52.

    What is GDRX's market cap?

    Goodrx Holdings Inc (GDRX) has a market capitalization of $1.15B with a current stock price of $3.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In